NOT FOR DISTRIBUTION
Header cover image

Market Cap

€4.6b

Last Updated

2021/04/14 17:31 UTC

Data Sources

Company Financials +

Executive Summary

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women’s and general health, eye health, gastrointestinal diseases, and toxicology worldwide. More Details


Snowflake Analysis

Flawless balance sheet with solid track record.


Similar Companies

Share Price & News

How has Quidel's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: QL1 is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: QL1's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.


Market Performance


7 Day Return

-2.1%

QL1

2.9%

DE Medical Equipment

0.2%

DE Market


1 Year Return

20.3%

QL1

41.5%

DE Medical Equipment

42.4%

DE Market

Return vs Industry: QL1 underperformed the German Medical Equipment industry which returned 41.5% over the past year.

Return vs Market: QL1 underperformed the German Market which returned 42.4% over the past year.


Shareholder returns

QL1IndustryMarket
7 Day-2.1%2.9%0.2%
30 Day-6.6%7.6%5.1%
90 Day-33.9%13.0%9.6%
1 Year20.3%20.3%43.2%41.5%47.0%42.4%
3 Year135.0%135.0%95.4%87.0%23.5%12.8%
5 Year556.9%556.9%338.7%322.5%51.0%29.5%

Long-Term Price Volatility Vs. Market

How volatile is Quidel's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Quidel undervalued compared to its fair value and its price relative to the market?

6.74x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: QL1 (€103.05) is trading above our estimate of fair value (€102.14)

Significantly Below Fair Value: QL1 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: QL1 is good value based on its PE Ratio (6.6x) compared to the DE Medical Equipment industry average (46.3x).

PE vs Market: QL1 is good value based on its PE Ratio (6.6x) compared to the German market (28.2x).


Price to Earnings Growth Ratio

PEG Ratio: QL1's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: QL1 is good value based on its PB Ratio (4x) compared to the DE Medical Equipment industry average (7.9x).


Future Growth

How is Quidel forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-8.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: QL1's earnings are forecast to decline over the next 3 years (-8.5% per year).

Earnings vs Market: QL1's earnings are forecast to decline over the next 3 years (-8.5% per year).

High Growth Earnings: QL1's earnings are forecast to decline over the next 3 years.

Revenue vs Market: QL1's revenue is expected to decline over the next 3 years (-8.4% per year).

High Growth Revenue: QL1's revenue is forecast to decline over the next 3 years (-8.4% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: QL1's Return on Equity is forecast to be low in 3 years time (7.9%).


Past Performance

How has Quidel performed over the past 5 years?

86.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: QL1 has a high level of non-cash earnings.

Growing Profit Margin: QL1's current net profit margins (48.8%) are higher than last year (13.7%).


Past Earnings Growth Analysis

Earnings Trend: QL1 has become profitable over the past 5 years, growing earnings by 86.3% per year.

Accelerating Growth: QL1's earnings growth over the past year (1008.6%) exceeds its 5-year average (86.3% per year).

Earnings vs Industry: QL1 earnings growth over the past year (1008.6%) exceeded the Medical Equipment industry 44.3%.


Return on Equity

High ROE: QL1's Return on Equity (60.8%) is considered outstanding.


Financial Health

How is Quidel's financial position?


Financial Position Analysis

Short Term Liabilities: QL1's short term assets ($1.1B) exceed its short term liabilities ($337.0M).

Long Term Liabilities: QL1's short term assets ($1.1B) exceed its long term liabilities ($201.5M).


Debt to Equity History and Analysis

Debt Level: QL1 is debt free.

Reducing Debt: QL1 has no debt compared to 5 years ago when its debt to equity ratio was 65.6%.

Debt Coverage: QL1 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: QL1 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Quidel current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate QL1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate QL1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if QL1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QL1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of QL1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Doug Bryant (62 yo)

12.08yrs

Tenure

US$4,168,766

Compensation

Mr. Douglas C. Bryant, also known as Doug, has been the Chief Executive Officer and President of Quidel Corp. since March 1, 2009. Mr. Bryant served as the Chief Operating Officer and Executive Vice Presid...


CEO Compensation Analysis

Compensation vs Market: Doug's total compensation ($USD4.17M) is about average for companies of similar size in the German market ($USD3.26M).

Compensation vs Earnings: Doug's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: QL1's management team is considered experienced (3.5 years average tenure).


Board Members

Experienced Board: QL1's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: QL1 insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Quidel Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Quidel Corporation
  • Ticker: QL1
  • Exchange: DB
  • Founded: 1979
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$5.485b
  • Listing Market Cap: US$4.597b
  • Shares outstanding: 42.32m
  • Website: https://www.quidel.com

Number of Employees


Location

  • Quidel Corporation
  • 9975 Summers Ridge Road
  • San Diego
  • California
  • 92121
  • United States

Listings


Biography

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women’s and general health, eye health, gastrointestinal di...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/14 17:31
End of Day Share Price2021/04/13 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.